Business Context and Reporting Period
This Form 8-K filing by MiMedx Group, Inc. was submitted on February 21, 2019. The report addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
On February 21, 2019, the Board of Directors granted two restricted stock awards and adjusted the compensation package for Edward Borkowski, EVP and Interim Chief Financial Officer. These awards were contemplated but not granted at the time of his initial joining.
- Restricted Stock Award 1: 100,000 shares vesting in three equal tranches (one-third immediately, one-third on the first anniversary, and one-third on the second anniversary).
- Restricted Stock Award 2: 103,305 shares vesting pro rata annually over two years.
- Salary Adjustment: Annual salary increased to $600,000, effective January 1, 2019.
- Bonus Target: Target annual performance bonus set at 65% of base salary.
- Long-Term Incentive: Target annual long-term equity incentive award set at 275% of annual base salary.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific executive compensation changes detailed above.
Investor Verification Checklist
- Verify the total number of restricted shares granted to Edward Borkowski (203,305 total).
- Confirm the vesting schedule details for both stock awards.
- Review the effective date of the salary increase (January 1, 2019).
- Check the specific percentages for the performance bonus (65%) and long-term equity incentive (275%).